Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine
Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine
复制标题
DOI：
10.1053/rmed.2003.1507
复制
发表时间：
2003-06-01
影响因子：
4.3
通讯作者：
Sozañska, E
中科院分区：
文献类型：
--
作者：
Barczyk, A;Pierzchala, W;Sozañska, E
背景：白细胞介素17（IL-17）是一种由活化的人类记忆CD4+ T细胞分泌的新型细胞因子。体内 IL-17 通过支气管上皮细胞释放 CXC 趋化因子（白细胞介素 8）将中性粒细胞募集到气道中。由于中性粒细胞与慢性阻塞性肺病 (COPD)、慢性支气管炎 (CB) 和哮喘的发病机制有关，我们假设这些患者气道中的 IL-17 浓度会增加。为了检验这一假设，我们测量了 COPD 患者、慢性支气管炎和哮喘患者的诱导痰中 IL-17 的水平，并将其与健康对照进行比较。方法：采用ELISA法测定19例COPD、16例CB、10例哮喘及对照组受试者诱导痰中IL-17水平。在 FEVI 高于预测值 70% 的人群中进行了气道对乙酰甲胆碱的反应。结果：对照组与其他组间U 17 水平无显着差异。然而，COPD患者痰中IL-17水平显着低于哮喘组（P=0.004）和CB组（P=0.01）。中位数和（范围）如下：哮喘 - 376 pg/ml（18.8-55.7 pg/ml）、CB 293 pg/ml（18.8-497 pg/ml）和 COPD 24.6 pg/ml（0-34.1 pg/ml）、健康对照受试者（PC20 > 8 mg/ml）与支气管高反应性组的比较，其中包括： PC20 低于 8 mg/ml 的哮喘患者和 CB 患者显示，第二组中 IL-17 水平显着升高（P=0.02）。此外，与健康受试者相比，支气管高反应性哮喘患者的 IL-17 水平显着升高（P=0.02）。此外，所有研究对象痰液中IL-17的水平与PC20呈负相关（r=-0.51，P=0.002）。结论：根据我们的结果，IL-17 可能与稳定型 COPD 的发病机制无关，但它可能在气道高反应性患者中发挥作用。 (C) 2003 Elsevier Science Ltd. 保留所有权利。
Background: Interleukin-17 (IL-17) is a novel cytolkine secreted by activated human memory CD4+ T cells. In vivo IL-17 recruits neutrophils into the airways via the release of CXC chemokines (interleukin-8) from bronchial epithelial cells. Since neutrophils are implicated in pathogenesis of chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB) and asthma, we hypothesized that there would be increased concentration of IL-17 in the airways of these patients. To test this hypothesis, we measured levels of IL-17 in induced sputum of COPD patients, chronic bronchitis and asthmatics and compared them with healthy controls. Methods: Levels of IL-17 in induced sputum were measured via ELISA method in 19 COPD, 16 CB, 10 asthma and I I control subjects. Airway responsiveness to methacholine was performed in people with FEVI higher than 70% of predicted. Results: There were no significant differences in U 17 levels between control group and the other groups. However, levels of IL-17 in sputum of COPD patients were significantly lower than in asthma (P=0.004) and in CB (P=0.01) groups. Medians and (ranges) were as follows: asthma-376 pg/ml (18.8-55.7 pg/ ml), CB 293 pg/ml (18.8-497 pg/ml) and COPD 24.6 pg/ml (0-34.1 pg/ml), Comparison of healthy control subjects (PC20 > 8 mg/ml) to a group with bronchial hyperreactivity, which consisted of asthmatics and CB patients, whose PC20 was less than 8 mg/ml, revealed that levels of IL-17 were significantly increased in the second group (P=0.02). Also, levels of IL-17 were significantly increased (P=0.02) in the asthmatic patients with bronchial hyperreactivity compared to healthy subjects. Moreover levels of IL-17 in sputum of all studied subjects correlated negatively with PC20 (r=-0.51, P=0.002). Conclusions: According to our results IL-17 is probably not involved in pathogenesis of stable COPD, but it may play a role in people with airway hyperresponsiveness. (C) 2003 Elsevier Science Ltd. All rights reserved.